Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imiglucerase - Sanofi

Next Previous
Drug Profile

Imiglucerase - Sanofi

Alternative Names: Cerecyme; Cerezyme; GZ 437843; Imiglucerase

Latest Information Update: 09 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi
  • Class Glucosidases
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gaucher's disease; Gaucher's disease type III
  • Phase III Gaucher's disease type I

Most Recent Events

  • 20 Nov 2025 Imiglucerase is still in phase III ELIKIDS trials for Gaucher's disease type I and Gaucher's disease type III (Combination therapy, In adolescents, In children, Treatment-experienced) in United Kingdom, Turkey, Sweden, Spain, Japan, Italy, France, Canada, Netherlands, Argentina, Russia (IV, Infusion) (NCT03485677)
  • 02 Jan 2023 Imiglucerase is still in phase III trials for Gaucher's disease type I in Argentina, Canada, France, Italy, Japan, Russian, Spain, Sweden, Turkey, Netherlands, United Kingdom
  • 02 Jan 2023 Imiglucerase is still in phase III trials for Gaucher's disease type III in Argentina, Canada, France, Italy, Japan, Russian, Spain, Sweden, Turkey, Netherlands, United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top